Form 4: Ocular Therapeutix CFO Donald Notman Receives Stock Options and Restricted Stock Units

Donald Notman, CFO and COO of Ocular Therapeutix, was granted stock options and restricted stock units (RSUs) on February 11, 2025.

Summary

• Donald Notman, the Chief Financial Officer and Chief Operating Officer of Ocular Therapeutix, Inc., received stock options and restricted stock units (RSUs) on February 11, 2025.
• He was granted 115,000 RSUs under the 2021 Stock Incentive Plan.
• These RSUs will vest over three years, with one-third vesting on the first anniversary of the grant date and an additional one-third vesting at the end of each successive year.
• Notman also received options to purchase 344,115 shares of common stock at an exercise price of $7.44.
• These options vest over four years, beginning one month after the grant date, vesting 1/48 monthly.
• Following these transactions, Notman directly owns 308,444 shares of common stock and options for 344,115 shares.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive as it reflects standard executive compensation practices that align management interests with shareholders.

Positives

• The grant of RSUs and stock options aligns the executive's interests with those of the shareholders.
• The vesting schedules encourage long-term commitment from the CFO and COO.

Future Outlook

The vesting schedules for the RSUs and stock options suggest a commitment to long-term value creation at Ocular Therapeutix.

Industry Context

Stock option and RSU grants are common practices in the pharmaceutical industry to incentivize executives and align their interests with shareholders.

Stakeholder Impact

• Shareholders may view the grants positively as they incentivize management to improve company performance.
• Employees may see the grants as a sign of confidence in the company's future.

Key Dates

Keywords

Ocular Therapeutix, Donald Notman, stock options, restricted stock units, RSUs, Form 4, insider trading, executive compensation